AARD CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Aardvark Therapeutics (NASDAQ: AARD) tied to its February 13, 2025 IPO and securities purchases through May 14, 2026. A federal securities class action has been filed, and investors seeking lead-plaintiff status face an October 13, 2026 deadline. The litigation introduces reputational and potential financial risk for the biotech company.

Analysis

This is primarily a litigation-overhang and liquidity event rather than a fundamental clinical read-through. For a recently public biotech, the relevant transmission mechanism is higher perceived disclosure risk: prospective crossover investors typically demand a wider discount to cash, while management may lose flexibility to raise capital before a meaningful data catalyst. The near-term price effect can be amplified by concentrated IPO-era holders and thin borrow availability, making both forced selling and shorting costly.

Over the next 1-3 months, the key issue is whether the complaint survives beyond an initial procedural stage and, more importantly, whether the alleged disclosure gap overlaps with any independently verifiable change in AARD's clinical, regulatory, or commercial assumptions. A plaintiff-deadline announcement alone has limited predictive value for damages or ultimate liability; absent a related guidance cut, trial delay, safety signal, or SEC inquiry, the stock reaction is more likely to mean-revert than compound. The 6-18 month risk is financing: a sustained discount to net cash can turn an otherwise manageable development budget into dilutive equity issuance.

Consensus may over-interpret the law-firm solicitation as new information. These notices often follow price declines and do not establish merit, so directional short exposure is unattractive unless borrow is available at a low carry and the underlying allegation identifies a concrete, measurable operating discrepancy. The more actionable setup is to monitor whether legal headlines create a disconnect between enterprise value and cash runway; if no fundamental catalyst is impaired, litigation-driven weakness can offer an event-driven entry rather than a durable bearish signal.

Key Decisions for Investors

• Do not initiate a standalone AARD short solely on this notice; reassess only if the complaint identifies a specific undisclosed clinical or regulatory fact and AARD confirms a trial, guidance, or cash-runway change. High borrow cost and biotech gap risk can make the short's carry asymmetrically unfavorable.
• Set a 1-3 month alert for AARD trading materially below estimated net cash per share while trial timelines and cash-burn guidance remain intact; investigate a small long only after verifying latest cash balance, quarterly burn, enrollment status, and potential financing needs.
• For existing AARD long exposure, reduce position sizing ahead of the October 13 lead-plaintiff deadline only if liquidity is limited; retain exposure only where the investment case is supported by a dated clinical catalyst rather than a litigation-resolution thesis.
• Watch SEC filings, trial-registry updates, and any financing registration statement over the next two quarters. A shelf filing or accelerated cash burn would validate the dilution-risk thesis and favor avoiding or hedging AARD; absence of these signals would weaken the litigation-driven bear case.